Active Ingredient(s): Entrectinib
FDA Approved: * August 15, 2019
Pharm Company: * GENENTECH INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rozlytrek Overview

Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.[3] It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).[3] The most common side effects include tiredness, constipation, dysgeusia (taste disturbances), edema (swelling with flui...

Read more Rozlytrek Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Rozlytrek Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 100mg, 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rozlytrek: (2 results)

Sorted by National Drug Code
  • 50242-091 Rozlytrek 100 mg Oral Capsule by Genentech Inc.
  • 50242-094 Rozlytrek 200 mg Oral Capsule by Genentech Inc.

Other drugs which contain Entrectinib or a similar ingredient: (1 result)